Applying PET-CT for predicting the efficacy of SBRT to inoperable early-stage lung adenocarcinoma: A Brazilian case-series.
Lancet Reg Health Am
; 11: 100241, 2022 Jul.
Article
en En
| MEDLINE
| ID: mdl-36778931
ABSTRACT
Background:
Stereotactic body radiotherapy (SBRT) is a treatment option for early-stage inoperable primary lung cancer. Here we report a thorough description of the prognostic value of pre-SBRT SUVmax for predicting the efficacy of SBRT in early-stage lung adenocarcinoma.Methods:
This is a retrospective study of consecutive cases of early-stage inoperable lung adenocarcinoma, staged with PET-CT, treated with SBRT between 2007 and 17. Kaplan-Meier (KM) curves were used to assess overall survival and compare time to event between those with PET-CT SUVmax values ≤ 5.0 and those > 5. Fisher's Exact tests and the Mann-Whitney U were used to compare the patient and clinical data of those with SUVmax≤5.0 and >5.0, and those with and without any failure.Findings:
Amongst 50 lung carcinoma lesions, from 47 patients (34 (68%)-T1a orInterpretation:
Patients with early-stage inoperable lung adenocarcinoma present good clinical outcomes when treated with SBRT. We raised the hypothesis that the value of PET-CT SUVmax before SBRT may be an important predictive factor in disease control.Funding:
None.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
País/Región como asunto:
America do sul
/
Brasil
Idioma:
En
Revista:
Lancet Reg Health Am
Año:
2022
Tipo del documento:
Article
País de afiliación:
Brasil